Q4 EPS Estimates for Zimmer Biomet Cut by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities researchers at Zacks Research dropped their Q4 2025 EPS estimates for shares of Zimmer Biomet in a note issued to investors on Monday, November 25th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $2.37 for the quarter, down from their prior forecast of $2.38. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share.

ZBH has been the topic of a number of other research reports. Raymond James decreased their target price on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Canaccord Genuity Group decreased their price objective on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a report on Tuesday, September 10th. Royal Bank of Canada raised their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Monday, November 4th. Wolfe Research initiated coverage on Zimmer Biomet in a report on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Finally, Wells Fargo & Company lifted their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $123.22.

Zimmer Biomet Trading Up 1.3 %

Shares of NYSE:ZBH opened at $112.06 on Thursday. Zimmer Biomet has a 1 year low of $101.47 and a 1 year high of $133.90. The firm has a market capitalization of $22.31 billion, a price-to-earnings ratio of 21.30, a price-to-earnings-growth ratio of 2.03 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The business’s 50 day moving average price is $107.07 and its 200-day moving average price is $109.49.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter last year, the company earned $1.65 EPS. The business’s revenue was up 4.1% on a year-over-year basis.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors have recently bought and sold shares of ZBH. Dunhill Financial LLC boosted its stake in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares during the period. Ashton Thomas Securities LLC purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $28,000. Bangor Savings Bank purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $31,000. Family Firm Inc. purchased a new position in shares of Zimmer Biomet in the 2nd quarter valued at about $33,000. Finally, Brooklyn Investment Group purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $35,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.